Nebivolol
Brand: Bystolic (US/EU) / Nebicard (IN) / Nebilet (BD)
Antihypertensive
Beta-1 selective blocker with vasodilatory action
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 1.5 h |
| Bioavailability | 12 % (approx) |
| Protein Binding | 98 % |
| Volume of Distribution | 10 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Metabolized by CYP2D6; slow metabolizers exhibit higher plasma levels; dual mechanism—β1 blockade and nitric-oxide-mediated vasodilation. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Headache, dizziness, fatigue, bradycardia, paresthesia
Contraindications:
Severe bradycardia, heart block, hepatic impairment
Precautions:
Adjust dose in hepatic dysfunction; avoid abrupt discontinuation; monitor for bradycardia and hypotension